Treatment Design
 
Colorectal cancer is the most diagnosed cancer in the European Union. These patients show a huge heterogeneity with regard to responsiveness to defined medical treatments. This diversity is anticipated to be a consequence of a complex interplay of genetic, proteomic, cellomic and external factors. 2cureX is developing a unique technology that selects the specific treatment based on the decisive cellular efficacy in tissue from the individual patient.

Identification of efficacious treatment regimen based on prospective testing.